

Ⅲ. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表レイアウト

書籍（日本語）

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
佐治重衡	患者さんのための乳がん診療ガイドライン	日本乳癌学会	患者さんのための乳がん診療ガイドライン	金原出版	-	2019	-
佐治重衡	乳癌診療ガイドライン追補2019-2018年版	日本乳癌学会	乳癌診療ガイドライン追補2019-2018年版	金原出版	-	2019	-

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Shiino S, Matsuzaki J, <u>Tamura K</u> et al.	Serum miRNA-based Prediction of Axillary Lymph Node Metastasis in Breast Cancer.	Clin Cancer Res.	25	1817-1827	2019
Noguchi E, <u>Tamura K</u> , Hattori M et al.	Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study.	Breast Cancer	26	39-46	2019
Yonemori K, Shimomura A, <u>Tamura K</u> et al.	A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.	Eur J Cancer	109	84-91	2019
Noda-Narita S, Shimomura A, <u>Tamura K</u> et al.	Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.	Breast Cancer	26	492-498	2019
Sunami K, Ichikawa H, <u>Tamura K</u> et al.	Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.	Cancer Sci	110	1480-1490	2019
Ito T, Kumagai Y, <u>Tamura K</u> et al.	Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification.	Biochem Biophys Res Commun.	511	544-550	2019
Turner NC, Alarcón E, <u>Tamura K</u> et al.	BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant subpopulation.	Ann Oncol.	30	774-780	2019

Hirakawa A, Sudo K, <u>Tamura K</u> et al.	A comparative study of longitudinal toxicities of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, and cancer vaccines.	Clin Pharmacol Ther	106	803-809	2019
Goto K, Fujiwara Y, <u>Tamura K</u> et al.	Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function.	Cancer Sci.	110	1987-1994	2019
<u>Tamura K</u> , Tsurutani J, Takahashi S et al.	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.	Lancet Oncol.	20	816-826	2019
Shitara K, Iwata H, <u>Tamura K</u> et al.	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.	Lancet Oncol.	20	827-836	2019
Yap YS, Lu YS, <u>Tamura K</u> et al.	Insights Into Breast Cancer in the East vs the West: A Review.	JAMA Oncol.	-	doi: 10.1001/jamaoncol.2019.0620	2019
Ebata T, Shimizu T, <u>Tamura K</u> et al.	Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.	Invest New Drugs	-	doi: 10.1007/s10637-019-00787-3	2019
<u>Tamura K</u> , Hasegawa K, Katsumata N et al.	Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: a multicenter, open-label phase 2 trial.	Cancer Sci.	110	2894-2904	2019
Shimomura A, Yonemori K, <u>Tamura K</u> et al.	Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.	Transl Oncol	12	1386-1394	2019
Kubo M, Kawai M, <u>Tamura K</u> et al.	A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.	Breast Cancer Res Treat	178	647-656	2019
Satomi-Tsushita N, Shimomura A, <u>Tamura K</u> et al.	Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer.	PLoS One.	14	e0222024. doi: 10.1371/journal.pone.0222024	2019

Nakano MH, Udagawa C, <u>Tamura K</u> et al.	A Genome-Wide Association Study Identifies Five Novel Genetic Markers for Trastuzumab-Induced Cardiotoxicity in Japanese Population.	Biol Pharm Bull.	42	2045-2053	2019
Sato J, Shimomura A, <u>Tamura K</u> et al.	Brain metastasis-related microRNAs in patients with advanced breast cancer.	PLoS One	14	e0221538. doi: 10.1371/journal.pone.0221538	2019
Kuroda T, Ogiwara H, <u>Tamura K</u> et al.	Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.	Gynecol Oncol.	155	489-498	2019
<u>Tamura K</u> , Imamura CK, Takano T et al.	<i>CYP2D6</i> Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.	J Clin Oncol.	-	doi: 10.1200/JCO.19.01412	2019
Modi S, Saura C, <u>Tamura K</u> et al.	DESTINY-Breast01 Investigators: Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.	N Engl J Med.	-	doi: 10.1056/NEJMoa1914510	2019
Noda-Narita S, Shimomura A, <u>Tamura K</u> et al.	Peripheral Neuropathy From Paclitaxel: Risk Prediction by Serum microRNAs	BMJ Support Palliat Care	-	doi: 10.1136/bmjspcare-2019-001900	2019
Okura N, Nishioka N, <u>Yano S</u> et al.	ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in <i>EGFR</i> -mutated non-small lung cancer.	Clin Cancer Res	-	pii: clincanres.2321	2020
Adachi Y, Yanagimura N, <u>Yano S</u> et al.	Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.	BMC Cancer	20	156	2020
Takeuchi S, Hase T, <u>Yano S</u> et al.	Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double-positive lung cancer.	Cancer Sci	111	561-570	2020
Peng S, Wang R, <u>Yano S</u> et al.	EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.	Mol Cancer.	18	165	2019
Ohtsubo K, Miyake K, <u>Yano S</u> et al.	Analyses of aberrant methylation of tumor suppressive miRNAs in bile in patients with pancreaticobiliary diseases.	Anticancer Res	39	5449-5459	2019

Kita K, Fukuda K, <u>Yano S</u> et al.	Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.	Cancer Sci,	110	3215-3224	2019
Staub Y, Nishiyama A, <u>Yano S</u> et al.	Clinical characteristics associated with lenvatinib-induced fistula and tumor-related bleeding in patients with thyroid cancer.	Anticancer Res.	39	3871-3878	2019
Adachi Y, <u>Yano S.</u>	Caput medusae-like venous dilations in lung cancer.	Internal Med.	-	doi: 10.2169/internalmedicine.2577-18	2019
Sakai K, Passioura T, <u>Yano S</u> et al.	Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor.	Nat Chem Biol	15	598-606	2019
Menyhart O, Kakisaka T, <u>Uetake H</u> et al.	Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes.	Cancers (Basel).	11	983. doi: 10.3390/cancers11070983.	2019
Kumaki Y, Takahashi K, <u>Uetake H</u> et al.	Clinical Utility of Comprehensive Genome Profiling Using FoundationOne CDx in Japanese Population (PROFILE-F Study)	Gan To Kagaku Ryoho.	46	1715-1719	2019
Tamura R, <u>Yoshihara K</u> , Nakaoka H et al.	XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary	Oncogene	39	3541-3554	2019
Tuna M, Ju Z, <u>Yoshihara K</u> , et al.	Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.	Br J Cancer	122	405-412.	2019
Sugino K, Tamura R, <u>Yoshihara K</u> et al.	Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients.	Sci Rep.	9	17808	2019